Anti-obesity Drugs Landscape and Its Impact on Medical Devices Industry
This blog explores the transformative impact of novel anti-obesity drugs, such as Tirzepatide, on the medical devices industry. With the approval of Tirzepatide (Zepbound) in late 2023, there has been a significant surge in interest and development within the anti-obesity drug market, projected to exceed US$ 100 billion by 2030. The article delves into how these advancements are reshaping treatment approaches, patient health outcomes, and the broader healthcare landscape